Brokerages Set Organon & Co. (NYSE:OGN) Price Target at $8.38

Organon & Co. (NYSE:OGN) has received an average recommendation of “Reduce” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $8.3750.

A number of research analysts recently issued reports on OGN shares. Morgan Stanley decreased their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Barclays started coverage on Organon & Co. in a research report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price objective on the stock. JPMorgan Chase & Co. cut their target price on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. Finally, Piper Sandler downgraded shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target on the stock. in a report on Monday, October 27th.

Institutional Trading of Organon & Co.

Several institutional investors have recently bought and sold shares of OGN. Hanson & Doremus Investment Management acquired a new position in shares of Organon & Co. during the 2nd quarter worth approximately $26,000. Hantz Financial Services Inc. increased its holdings in Organon & Co. by 293.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after acquiring an additional 1,995 shares in the last quarter. Foster Dykema Cabot & Partners LLC acquired a new position in Organon & Co. during the third quarter worth $29,000. Ransom Advisory Ltd purchased a new position in Organon & Co. during the first quarter valued at $32,000. Finally, SouthState Corp lifted its holdings in Organon & Co. by 1,857.0% during the second quarter. SouthState Corp now owns 3,914 shares of the company’s stock valued at $38,000 after purchasing an additional 3,714 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

Shares of OGN opened at $7.10 on Wednesday. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.20 and a current ratio of 1.75. The stock has a 50-day moving average of $7.49 and a two-hundred day moving average of $9.05. The stock has a market cap of $1.84 billion, a P/E ratio of 3.70, a P/E/G ratio of 1.49 and a beta of 0.57. Organon & Co. has a one year low of $6.18 and a one year high of $17.23.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.08. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period last year, the business posted $1.38 earnings per share. As a group, research analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Thursday, November 20th. Organon & Co.’s dividend payout ratio is presently 4.17%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.